FDA OKs first pill in U.S. to reduce hay-fever allergies - 8 News NOW

'Ah-choo': FDA OKs first pill to reduce hay-fever allergies

Posted: Updated:
  • Paula's Health NotesLas Vegas Health NewsMore>>

  • Why some patients don't get Alzheimer's

    Why some patients don't get Alzheimer's

    Friday, August 29 2014 4:23 PM EDT2014-08-29 20:23:01 GMT
     new study may help scientists unlock a medical mystery. Researchers have found that rheumatoid arthritis patients seem to have protection from developing Alzheimer's disease. The scientific link between the two may help researchers develop a new treatment for Alzheimer's.More>>
     new study may help scientists unlock a medical mystery. Researchers have found that rheumatoid arthritis patients seem to have protection from developing Alzheimer's disease. The scientific link between the two may help researchers develop a new treatment for Alzheimer's.More>>
  • Brain surgery through the nose

    Brain surgery through the nose

    Friday, August 29 2014 3:00 PM EDT2014-08-29 19:00:17 GMT
    Removing a brain tumor can be tricky for surgeons and painful for patients. Now there's a new way to take out these lesions as surgeons are using the nose as a pathway to the brain.More>>
    Removing a brain tumor can be tricky for surgeons and painful for patients. Now there's a new way to take out these lesions as surgeons are using the nose as a pathway to the brain.More>>
  • New procedure to help Lipedema

    New procedure to help Lipedema

    Friday, August 22 2014 3:55 PM EDT2014-08-22 19:55:58 GMT
    Some women just can't lose weight and for the estimated 11 percent of women with a chronic disorder, diet and exercise won't help at all. Now, there is a new procedure doctors are now using that can help restore their appearance.More>>
    Some women just can't lose weight and for the estimated 11 percent of women with a chronic disorder, diet and exercise won't help at all. Now, there is a new procedure doctors are now using that can help restore their appearance.More>>

TRENTON, N.J. (AP) -- The Food and Drug Administration said Wednesday that it has approved the first tablet in the U.S. for gradually reducing hay fever symptoms, an alternative to months of weekly doctor visits for uncomfortable allergy-desensitizing shots.

Oralair was approved for patients ages 10 through 65. It's made by France's Stallergenes SA, a leader in immunotherapy medicines that dissolve under the tongue.

Oralair tablets are to be taken daily starting four months before grass pollen season to reduce allergic reactions to the five most common U.S. grass types: Kentucky bluegrass, orchard, perennial rye, sweet vernal and Timothy. It contains freeze-dried extracts from pollens of those grasses.

Meanwhile, drugmaker Merck & Co. of Whitehouse Station, N.J., expects an FDA ruling by midyear on its two experimental immunotherapy tablets, one for ragweed and one for grass pollen allergies. Merck is a leader in respiratory treatments, selling Claritin allergy pills and Nasonex allergy spray, multiple asthma inhalers and Singulair, a former $5 billion-a-year allergy and asthma pill now available as an inexpensive generic.

About 60 million Americans have hay fever, but fewer than 3 million are treated with allergy shots. Until now, their only other option was medicines to temporarily relieve sneezing, runny nose, congestion, watery eyes and itchy eyes and nose.

In patient testing over one grass pollen season, Oralair reduced symptoms and need for medication by 16 percent to 30 percent, versus dummy tablets.

Common side effects include throat irritation and mouth swelling. Severe allergic reactions, including life-threatening ones, are possible. For that reason, the first dose is given at a doctor's office, where the patient is watched for potential problems.

Oralair was approved in Europe in 2008 and is approved for sale in 31 countries, including Canada, Australia and Russia.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KLAS. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.